Is the Success of Cefazolin plus Ertapenem in Methicillin- Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?

Dan Smelter, Mary Hayney, George Sakoulas, Warren Rose

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Cefazolin and ertapenem have been shown to be an effective salvage regimen for refractory methicillin-susceptible Staphylococcus aureus bacteremia. Our findings suggest cefazolin plus ertapenem in vitro stimulates interleukin-1b release from peripheral blood monocytes both with and without S. aureus presence. This IL- 1b augmentation was primarily driven by ertapenem. These findings support further exploration of cefazolin plus ertapenem in MSSA bacteremia and may partially explain its marked potency in vivo despite modest synergy in vitro.

Original languageEnglish (US)
Article numbere02166-21
JournalAntimicrobial agents and chemotherapy
Volume66
Issue number2
DOIs
StatePublished - Feb 2022
Externally publishedYes

Keywords

  • Antimicrobial combinations
  • Beta-lactams
  • Immunology
  • In vitro
  • Innate immunity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Is the Success of Cefazolin plus Ertapenem in Methicillin- Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?'. Together they form a unique fingerprint.

Cite this